Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentBeginning Cash BalanceBeginning Cash BalanceCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares IssuedShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Picard Medical (PMI) Net Cash Flow (2024 - 2026)

Picard Medical posted quarterly Net Cash Flow of -$11.3 million for Q1 2026, down 2013.66% year-on-year from $593000.0 in Q1 2025, and down 231.34% on a QoQ basis from $8.6 million in Q4 2025.

Picard Medical (PMI) has 3 years of Net Cash Flow data on file, last reported at -$11.3 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Cash Flow fell 2013.66% year-over-year to -$11.3 million; the trailing twelve-month figure through Mar 2026 stood at -$536000.0 (down 190.24% YoY), and the FY2025 full-year result was $11.4 million, up 8675.19% from the prior year.
  • Net Cash Flow for Q1 2026 stood at -$11.3 million, down from $8.6 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $8.6 million in Q4 2025 and bottomed at -$11.3 million in Q1 2026.
  • The 3-year median for Net Cash Flow is $81000.0 (2024), against an average of $8285.7.
  • The widest annual swing landed in 2025, when Net Cash Flow soared 10566.67%; it then plunged 2013.66% in 2026.
  • A 3-year view of Net Cash Flow shows it stood at $81000.0 in 2024, then jumped by 10566.67% to $8.6 million in 2025, then slumped by 231.34% to -$11.3 million in 2026.
  • The last three Net Cash Flow figures came in at -$11.3 million (Q1 2026), $8.6 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -1.70 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -1.11 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -159.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -503.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -500.20 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -282.15 Mn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 202.10 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -2.19 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn 20.30 Mn
10 Picard Medical 12.10 Mn 12.10 Mn 275,000.00 -11.35 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -11.35 Mn
Mar 31, 2026 -11.35 Mn
Dec 31, 2025 8.64 Mn
Dec 31, 2025 8.64 Mn
Sep 30, 2025 2.44 Mn
Sep 30, 2025 2.44 Mn
Dec 31, 2024 81,000.00
Dec 31, 2024 81,000.00
Sep 30, 2024 -80,000.00
Sep 30, 2024 -80,000.00